Our results indicate that xyloketal B reduces UCP-2 mRNA expression, leading us to deduce that the effect of xyloketal B on NAFLD may be due to the down-regulation of UCP2 mRNA expression, These results are in accordance with previous studies [43,44]. Here, UCP2 is linked to metabolic dysfunction-associated steatotic liver disease.